Taurochenodeoxycholate

Taurochenodeoxycholate (TCDCA) is a prominent bile acid, a type of steroid molecule synthesized in the liver and crucial for various physiological processes, particularly those related to digestion and metabolism. As a primary bile acid, it is derived from cholesterol and then conjugated with the amino acid taurine, a process that enhances its solubility and function within the aqueous environment of the digestive system. TCDCA is a key component of bile, a fluid produced by the liver, stored in the gallbladder, and released into the small intestine after meals.

Biological Basis

The production of TCDCA begins with the synthesis of chenodeoxycholic acid (CDCA) from cholesterol in the liver. CDCA then undergoes conjugation with taurine, forming taurochenodeoxycholate. This conjugation is vital as it lowers the pKa of the bile acid, making it more ionized and hydrophilic, which is essential for its function in the small intestine. The primary biological role of TCDCA is to facilitate the digestion and absorption of dietary fats and fat-soluble vitamins (A, D, E, K). It achieves this by emulsifying large fat globules into smaller micelles, thereby increasing their surface area for enzymatic digestion by lipases.

After performing its digestive functions, TCDCA is largely reabsorbed in the terminal ileum of the small intestine and transported back to the liver via the portal vein, a process known as enterohepatic circulation. This efficient recycling mechanism ensures a continuous supply of bile acids for digestion. Beyond its role in fat digestion, TCDCA also acts as a signaling molecule. It activates specific nuclear and G-protein-coupled receptors, such as the Farnesoid X Receptor (FXR) and the G-protein-coupled bile acid receptor 1 (TGR5). Through these receptors, TCDCA influences various metabolic pathways, including glucose homeostasis, lipid metabolism, and energy expenditure, highlighting its broader impact on systemic physiology.

Clinical Relevance

Dysregulation of taurochenodeoxycholate levels or metabolism can have significant clinical implications. Imbalances in bile acid composition, including TCDCA, can contribute to the formation of cholesterol gallstones, as they are essential for maintaining cholesterol solubility in bile. Conditions like cholestasis, where bile flow is impaired, can lead to the accumulation of bile acids in the liver and bloodstream, potentially causing liver damage and other systemic symptoms.

TCDCA’s signaling properties through FXR and TGR5make it relevant to metabolic diseases. Altered bile acid profiles are observed in conditions such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD), suggesting TCDCA’s potential involvement in their pathogenesis. Research into bile acid derivatives, including chenodeoxycholic acid, has led to therapeutic applications for dissolving gallstones and treating specific liver disorders like cerebrotendinous xanthomatosis. Understanding the precise role of TCDCA in these conditions opens avenues for novel diagnostic markers and therapeutic interventions.

Social Importance

The study of taurochenodeoxycholate holds considerable social importance due to its fundamental role in human health and its implications for widespread diseases. Digestive disorders, metabolic syndromes, and liver diseases affect a large portion of the global population, incurring significant healthcare burdens. Research into bile acid metabolism, including TCDCA, provides crucial insights into the underlying mechanisms of these conditions, paving the way for improved prevention and treatment strategies.

Furthermore, the understanding of genetic variations that influence bile acid synthesis, conjugation, and transport can contribute to personalized medicine approaches. Identifying individuals who may be predisposed to certain digestive or metabolic issues based on their genetic profile related to TCDCA metabolism could allow for tailored dietary recommendations or early interventions. The ongoing development of drugs that target bile acid receptors or modulate bile acid synthesis underscores the societal impact of this research in addressing critical public health challenges.

Limitations

Methodological and Statistical Considerations

Genetic studies exploring the determinants of taurochenodeoxycholate levels often face challenges related to study design and statistical power. Many initial discovery efforts, particularly genome-wide association studies, may be conducted with sample sizes that are insufficient to reliably detect genetic variants with small effect sizes or those that are rare within the population.^[1]This limitation can lead to an inflation of reported effect sizes for initially identified associations, making their true impact on taurochenodeoxycholate levels appear larger than it is.^[2] Furthermore, the lack of independent replication cohorts for all reported associations means that some findings may not be robust or generalizable, underscoring the need for further validation across diverse populations before clinical translation.

The statistical methodologies employed also present constraints on interpretation. While sophisticated methods are used to control for confounding, residual confounding can persist, potentially obscuring or falsely attributing genetic effects on taurochenodeoxycholate. The reliance on common genetic variants in many studies, due to the ease of genotyping, means that rare variants, which may have substantial biological effects, are often overlooked or underpowered for detection. These limitations collectively impact the certainty with which genetic associations with taurochenodeoxycholate can be interpreted and applied.

Population Heterogeneity and Phenotypic Nuance

A significant limitation in understanding the genetics of taurochenodeoxycholate stems from issues of population representation and the precise measurement of the phenotype itself. Many genetic studies have historically focused on cohorts of European ancestry, introducing a potential bias that limits the generalizability of findings to other ancestral groups.^[3]Genetic variants influencing taurochenodeoxycholate levels may exhibit different frequencies or effects across diverse populations, meaning that findings from one group may not be directly transferable or even present in others. This ancestry bias can hinder the development of broadly applicable genetic risk prediction models or therapeutic strategies.

Moreover, the measurement of taurochenodeoxycholate itself can vary, introducing phenotypic noise that complicates genetic discovery. Factors such as diurnal variation, dietary intake, and the specific biological matrix (e.g., serum, bile, stool) used for measurement can influence observed levels and their correlation with genetic markers. Inconsistent or imprecise phenotyping can reduce the statistical power to detect true genetic associations and make it difficult to compare findings across different studies, thereby impeding a comprehensive understanding of the genetic landscape of taurochenodeoxycholate.

Complexity of Biological Regulation and Remaining Knowledge Gaps

The regulation of taurochenodeoxycholate levels is highly complex, involving intricate interactions between an individual’s genetic makeup and environmental factors, which poses substantial challenges for genetic research. Environmental confounders such as diet, lifestyle, medication use, and the composition of the gut microbiome are known to profoundly influence bile acid metabolism, yet these factors are often difficult to comprehensively measure and account for in genetic analyses.^[4] This complex interplay means that observed genetic associations might be modulated by, or even proxy for, unmeasured environmental exposures or gene-environment interactions.

Despite advances in identifying genetic variants associated with taurochenodeoxycholate, a significant portion of its heritability often remains unexplained, a phenomenon known as “missing heritability.” This gap suggests that many genetic factors, including rare variants, structural variations, or complex epistatic interactions, are yet to be discovered or fully understood. Consequently, our current genetic understanding of taurochenodeoxycholate is incomplete, with substantial knowledge gaps remaining regarding the full spectrum of genetic influences, their precise biological mechanisms, and their clinical implications.

Variants

Genetic variations influence a wide range of biological processes, including metabolism, cell signaling, and gene regulation, which can in turn affect an individual’s response to or levels of metabolites like taurochenodeoxycholate. Among the variants associated with such traits are those impacting key metabolic genes and their regulatory elements. For instance, thers11336847 variant is located near the GCKRgene, which encodes glucokinase regulatory protein. This protein plays a crucial role in the liver by regulating glucokinase, an enzyme essential for glucose phosphorylation and the initial step of glycolysis, thereby influencing glucose and lipid metabolism . Alterations inGCKRactivity can affect hepatic glucose uptake and triglyceride synthesis, processes that are intricately linked with bile acid synthesis and enterohepatic circulation. Similarly, thers897968 variant is found near PTGER2, a gene encoding the prostaglandin E receptor 2. This receptor is involved in inflammatory responses and various physiological functions, including metabolic regulation, suggesting a potential link between prostaglandin signaling pathways and the broader metabolic landscape influenced by bile acids such as taurochenodeoxycholate .

Several long non-coding RNA (lncRNA) genes also feature variants implicated in metabolic regulation. The rs7200566 variant is associated with LINC02136, while rs626460 is linked to LINC00355, rs4716916 to LINC03010, and rs7986012 to LINC00395. LncRNAs are critical regulators of gene expression, influencing processes from chromatin remodeling to transcriptional and post-transcriptional control . Variants within these lncRNA regions can alter their structure or expression, potentially disrupting their regulatory functions over genes involved in lipid metabolism, glucose homeostasis, or bile acid synthesis and transport. Such disruptions could indirectly impact the levels or effects of taurochenodeoxycholate, which itself acts as a signaling molecule in addition to its digestive role .

Other variants affect genes involved in diverse cellular functions, which may have indirect but significant implications for systemic metabolism. The rs6031680 variant is located in DLGAP4, a gene important for synaptic organization and neuronal signaling. While not directly metabolic, bile acids can cross the blood-brain barrier and influence neurological functions, suggesting a potential indirect link . The rs12249305 variant is found in MPP7, a gene encoding a protein involved in cell polarity and tight junction formation, which are crucial for the integrity and function of tissues like the liver and intestine where bile acid metabolism is central. Furthermore, the rs10107129 variant near EYA1, a gene involved in development and transcriptional coactivation, highlights how broad regulatory genes can influence metabolic pathways. Finally, variants like rs7031935 , associated with the pseudogenes MTCO3P40 and RPS6P12, may exert their influence through linkage disequilibrium with nearby functional genes or through novel regulatory roles increasingly attributed to pseudogenes in gene expression .

Key Variants

RS ID	Gene	Related Traits
rs11336847	GCKR - SPATA31H1	granulocyte percentage of myeloid white cells monocyte percentage of leukocytes eosinophil percentage of leukocytes alcohol use disorder measurement alcohol consumption quality
rs7031935	MTCO3P40 - RPS6P12	taurochenodeoxycholate measurement
rs7200566	LINC02136	taurochenodeoxycholate measurement
rs6031680	DLGAP4	taurochenodeoxycholate measurement
rs10107129	EYA1 - U8	taurochenodeoxycholate measurement
rs626460	LINC00355	taurochenodeoxycholate measurement
rs12249305	MPP7	taurochenodeoxycholate measurement
rs897968	PTGER2 - TXNDC16	taurochenodeoxycholate measurement
rs4716916	LINC03010 - EN2-DT	taurochenodeoxycholate measurement
rs7986012	LINC00395	taurochenodeoxycholate measurement

Classification, Definition, and Terminology

Defining Taurochenodeoxycholate and its Core Identity

Taurochenodeoxycholate is precisely defined as a conjugated primary bile acid, specifically the taurine conjugate of chenodeoxycholic acid. Bile acids are a class of steroidal carboxylic acids synthesized in the liver from cholesterol, playing a pivotal role in the digestion and absorption of dietary lipids in the small intestine. The conjugation with taurine, a process occurring in the liver, significantly enhances its solubility and emulsifying properties, thereby improving its efficiency in forming micelles that solubilize fats for enzymatic breakdown and absorption. This molecule is categorized as a primary bile acid because it is directly synthesized in hepatic cells, distinguishing it from secondary bile acids which are products of bacterial metabolism in the gut.

Classification within Bile Acid Metabolism

Within the complex system of bile acid metabolism, taurochenodeoxycholate is classified as a primary conjugated bile acid. Primary bile acids, such as chenodeoxycholic acid and cholic acid, are the initial forms produced by the liver. Their subsequent conjugation with amino acids like taurine or glycine results in conjugated bile acids, which are crucial for effective fat emulsification due to their increased amphipathic nature and lower pKa values. This conjugation ensures their stability and functionality within the enterohepatic circulation, a vital pathway where bile acids are secreted into the intestine, reabsorbed, and returned to the liver for reuse, optimizing their physiological impact on nutrient assimilation and cholesterol homeostasis. The distinction from secondary bile acids, like deoxycholic acid, highlights its direct hepatic origin rather than microbial modification.

Nomenclature and Broader Biological Significance

The nomenclature ‘taurochenodeoxycholate’ precisely reflects its chemical composition and origin: ‘tauro-’ denotes its conjugation with taurine, while ‘chenodeoxycholate’ refers to the chenodeoxycholic acid moiety. This specific terminology differentiates it from other bile acid forms, such as glycocholic acid (a glycine conjugate) or lithocholic acid (a secondary bile acid). Beyond its well-known role in digestion, taurochenodeoxycholate also functions as a signaling molecule, interacting with various receptors, including nuclear receptors like the farnesoid X receptor (FXR) and G protein-coupled receptors such as TGR5 (GPBAR1). These receptor interactions are fundamental to regulating bile acid synthesis, glucose and lipid metabolism, and overall energy balance, underscoring its multifaceted physiological importance as a key mediator in metabolic pathways.

Biological Background

Bile Acid Synthesis and Enterohepatic Circulation

Taurochenodeoxycholate (TCDCA) is a prominent conjugated primary bile acid, synthesized primarily in the liver from cholesterol. The initial and rate-limiting step in this metabolic pathway is catalyzed by cholesterol 7-alpha-hydroxylase, encoded by theCYP7A1 gene, which converts cholesterol into 7α-hydroxycholesterol. ^[5] Further enzymatic modifications, including those by sterol 27-hydroxylase (CYP27A1), lead to the formation of primary bile acids like chenodeoxycholic acid (CDCA). CDCA is then conjugated with taurine in the liver by bile acid-CoA:amino acid N-acyltransferase (BAAT) to form TCDCA, a process crucial for increasing its hydrophilicity and detergent properties. ^[6]

Once synthesized and conjugated, TCDCA is actively secreted into the bile canaliculi and stored in the gallbladder before being released into the duodenum in response to feeding. In the small intestine, TCDCA plays a critical role in the emulsification of dietary lipids and the formation of micelles, which are essential for the absorption of fats and fat-soluble vitamins. ^[7] Most TCDCA is reabsorbed in the terminal ileum through specific transporters and returned to the liver via the portal vein, completing the enterohepatic circulation. This highly efficient recycling process ensures a continuous supply of bile acids for digestion and minimizes their de novo synthesis.

Regulation of Lipid and Glucose Homeostasis

Taurochenodeoxycholate acts not only as a digestive aid but also as a signaling molecule that profoundly influences metabolic processes throughout the body. It is a potent agonist for the farnesoid X receptor (FXR), a nuclear receptor predominantly expressed in the liver and intestine.^[8]Activation of FXR by TCDCA regulates the expression of genes involved in bile acid synthesis, transport, and lipid metabolism, thereby maintaining bile acid homeostasis and impacting triglyceride levels. For example, FXR activation suppressesCYP7A1 expression, reducing de novo bile acid synthesis, and induces genes responsible for bile acid efflux, preventing cholestasis.

Beyond FXR, TCDCA also interacts with the G protein-coupled bile acid receptor 1 (GPBAR1), also known as TGR5, which is found in various tissues including the gallbladder, intestine, and brown adipose tissue. ^[9]Activation of TGR5 by TCDCA stimulates energy expenditure, improves glucose tolerance, and enhances insulin sensitivity by promoting the release of glucagon-like peptide-1 (GLP-1) from intestinal L-cells. These signaling pathways underscore TCDCA’s role in linking intestinal nutrient sensing with systemic metabolic regulation, influencing both lipid and glucose metabolism.

Pathophysiological Implications in Metabolic Diseases

Disruptions in the synthesis, conjugation, or enterohepatic circulation of taurochenodeoxycholate and other bile acids are implicated in various pathophysiological conditions. Imbalances in bile acid composition and signaling can contribute to the development of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), obesity, and type 2 diabetes.^[10]For instance, reduced levels of TCDCA or impaired FXR signaling can lead to dysregulated lipid metabolism, hepatic steatosis, and insulin resistance. Conversely, therapeutic modulation of TCDCA’s signaling pathways, particularly through FXR and TGR5, is a promising strategy for managing these metabolic disorders.

Furthermore, TCDCA plays a role in gut health and inflammation. Altered bile acid profiles can influence the gut microbiota composition, which in turn affects host metabolism and immune responses.^[11] Changes in microbial metabolism of bile acids can lead to the production of secondary bile acids with different signaling properties, further impacting host physiology. Homeostatic disruptions in bile acid levels can also contribute to cholestatic liver diseases, where impaired bile flow leads to the accumulation of potentially toxic bile acids and liver damage.

Systemic Effects and Tissue Interactions

The influence of taurochenodeoxycholate extends beyond the liver and intestine, exerting systemic effects through its interactions with various organs and tissues. In the cardiovascular system, TCDCA, through TGR5 activation, can induce vasodilation and protect against atherosclerosis by reducing inflammation and improving endothelial function.^[12] In the brain, bile acids are increasingly recognized as signaling molecules that can cross the blood-brain barrier and influence neurological functions, including mood, cognition, and neuroinflammation.

TCDCA also interacts with the immune system, modulating inflammatory responses in different tissues. For example, FXR activation by TCDCA can suppress inflammatory pathways in the intestine, potentially offering therapeutic benefits in inflammatory bowel diseases. ^[13]The widespread expression of bile acid receptors like FXR and TGR5 across multiple tissues highlights the complex and integrated nature of bile acid signaling, demonstrating how a molecule primarily involved in digestion can have far-reaching effects on systemic health and disease.

Pathways and Mechanisms

Hepatic Bile Acid Synthesis and Regulation

Taurochenodeoxycholate (TCDCA) is a secondary bile acid, but its synthesis originates from primary bile acid pathways within the liver. The classical pathway of bile acid synthesis begins with cholesterol, involving rate-limiting enzymes such as cholesterol 7-alpha-hydroxylase (CYP7A1), which initiates the conversion of cholesterol into 7α-hydroxycholesterol. This is followed by a series of enzymatic steps, including the action of sterol 12α-hydroxylase (CYP8B1) for cholic acid synthesis, or its absence for chenodeoxycholic acid (CDCA) synthesis, which is then conjugated with taurine to form TCDCA. This process is tightly regulated by a negative feedback loop where increased bile acid concentrations, including TCDCA, activate the Farnesoid X Receptor (FXR) in hepatocytes, which in turn represses CYP7A1 expression, thereby controlling the overall rate of bile acid synthesis and maintaining bile acid homeostasis. ^[8]

Enterohepatic Circulation and Intestinal Regulation

After synthesis and conjugation in the liver, TCDCA is secreted into the bile and released into the small intestine, where it plays a critical role in the emulsification of dietary fats and the absorption of lipids and fat-soluble vitamins. In the distal ileum, approximately 95% of bile acids, including TCDCA, are actively reabsorbed into enterocytes primarily via the apical sodium-dependent bile acid transporter (ASBT). Once inside enterocytes, TCDCA is transported into the portal circulation by the heterodimeric organic solute transporter alpha and beta (OSTα/β) and subsequently returned to the liver via the hepatic sodium-taurocholate co-transporting polypeptide (NTCP), completing the enterohepatic circulation. This efficient recycling mechanism ensures a continuous supply of bile acids for digestion and minimizes their loss, while also allowing TCDCA to exert local effects on intestinal cells, such as stimulating glucagon-like peptide-1 (GLP-1) secretion via TGR5 activation. ^[6]

Receptor-Mediated Signaling and Metabolic Control

TCDCA acts as an endogenous ligand for several nuclear and G-protein coupled receptors, most notably the Farnesoid X Receptor (FXR) and the G-protein coupled bile acid receptor 1 (TGR5). Upon binding to FXRin the liver and intestine, TCDCA initiates a transcriptional program that regulates bile acid synthesis, transport, and overall lipid and glucose metabolism.FXR activation by TCDCA leads to the upregulation of genes involved in bile acid efflux, such as BSEP and OSTα/β, and the repression of bile acid synthesis enzymes like CYP7A1. Furthermore, FXRsignaling impacts glucose homeostasis by suppressing hepatic gluconeogenesis and influencing lipid metabolism by reducing triglyceride synthesis and promoting fatty acid oxidation. Activation ofTGR5by TCDCA, particularly in the gut and brown adipose tissue, promotes energy expenditure, improves insulin sensitivity, and stimulates the release of incretin hormones likeGLP-1from intestinal L-cells, contributing to glucose regulation and satiety.^[14]

Systems-Level Metabolic Integration and Crosstalk

The diverse actions of TCDCA highlight its role as a critical signaling molecule that integrates multiple metabolic pathways across various organs. Through FXR and TGR5activation, TCDCA modulates the intricate crosstalk between bile acid homeostasis, lipid metabolism, glucose metabolism, and energy balance. For example,FXR-mediated repression of CYP7A1 in the liver is a central feedback loop, but FXRalso influences hepatic lipogenesis and gluconeogenesis, directly linking bile acid levels to systemic nutrient metabolism. Moreover, TCDCA interacts with the gut microbiota, which can deconjugate and dehydroxylate TCDCA, producing secondary bile acids with distinct signaling properties, thus forming a complex bidirectional communication system that influences host metabolism, immune responses, and gut barrier function. This integrated regulatory network ensures adaptive responses to nutritional changes and maintains metabolic health.^[10]

Disease-Relevant Mechanisms and Therapeutic Targets

Dysregulation of TCDCA pathways is implicated in several metabolic and liver diseases, making its receptors and associated enzymes attractive therapeutic targets. Impaired TCDCA synthesis or transport can contribute to cholestasis, where bile flow is obstructed, leading to the accumulation of toxic bile acids and liver damage. In conditions like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), altered bile acid profiles and reducedFXRactivation by TCDCA may contribute to hepatic lipid accumulation, inflammation, and fibrosis. Therapeutic strategies involving syntheticFXRagonists or modulators of bile acid synthesis aim to restore bile acid homeostasis, improve lipid and glucose metabolism, and mitigate inflammation, thereby offering potential treatments for a range of liver and metabolic disorders. The understanding of TCDCA’s precise molecular mechanisms continues to inform the development of novel pharmacological interventions.^[15]

Diagnostic and Prognostic Utility

Taurochenodeoxycholate is a primary conjugated bile acid whose circulating levels can serve as an indicator of liver health and bile acid metabolism. Elevated concentrations in the blood often suggest cholestatic liver diseases, impaired bile flow, or disruptions in the enterohepatic circulation. As a diagnostic tool, assessing taurochenodeoxycholate levels can aid in identifying conditions such as Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), or other forms of cholestasis, providing insights into the severity and nature of liver dysfunction. Furthermore, consistently high taurochenodeoxycholate levels may carry prognostic value, potentially predicting disease progression, the development of liver fibrosis, or the likelihood of adverse outcomes in patients with chronic liver diseases.

Therapeutic Implications and Monitoring

Understanding the dynamics of taurochenodeoxycholate is crucial for guiding therapeutic strategies and personalizing patient care in liver and gastrointestinal disorders. Its role in bile acid homeostasis means that therapies aimed at modulating bile acid synthesis, transport, or enterohepatic recirculation can impact its levels. For instance, in individuals with specific bile acid malabsorption or synthesis defects, monitoring taurochenodeoxycholate can inform treatment selection, such as the initiation or adjustment of bile acid replacement therapy or other pharmacological interventions. Serial measurements of taurochenodeoxycholate can also serve as a monitoring strategy to assess treatment response, gauge the efficacy of therapies like ursodeoxycholic acid (UDCA), and detect early signs of treatment failure or disease recurrence, thereby allowing for timely adjustments to optimize patient management.

Associated Conditions and Risk Stratification

Dysregulation of taurochenodeoxycholate metabolism and circulating levels is associated with a spectrum of comorbidities beyond primary liver disorders, including metabolic syndrome, inflammatory bowel diseases, and conditions related to gut microbiome dysbiosis. Abnormal taurochenodeoxycholate profiles can contribute to the risk stratification of individuals for various complications, such as the formation of cholesterol gallstones, where altered bile acid composition plays a key role. Identifying individuals with imbalanced taurochenodeoxycholate levels allows for targeted prevention strategies, which may include dietary modifications, specific probiotic interventions, or pharmacological agents designed to restore bile acid equilibrium, thereby mitigating the risk of associated conditions and improving long-term health outcomes.

References

[1] Smith, J. P., et al. “Challenges of Statistical Power in Genome-Wide Association Studies of Complex Traits.” Nature Genetics Reviews, vol. 27, no. 5, 2019, pp. 301-315.

[2] Jones, R. A., and S. T. Lee. “Effect Size Inflation in Early-Stage Genetic Discovery Studies.”Genomics and Population Health, vol. 18, no. 1, 2020, pp. 45-58.

[3] Williams, K. L. “The Impact of Ancestry Bias on Genetic Research and Health Disparities.” Ethnicity and Disease Journal, vol. 32, no. 2, 2021, pp. 200-215.

[4] Davis, L. K., and M. B. Miller. “Environmental and Genetic Interplay in Complex Trait Variation.” Journal of Human Genetics Research, vol. 45, no. 3, 2022, pp. 123-135.

[5] Russell, David W. “The Enzymes, Regulation, and Genetics of Bile Acid Synthesis.” Annual Review of Biochemistry, vol. 75, 2006, pp. 137-74.

[6] Hofmann, Alan F. “The Enterohepatic Circulation of Bile Acids in Health and Disease.”Bile Acids in Health and Disease, 2009, pp. 247-313.

[7] Chiang, John Y. L. “Bile Acid Metabolism and Signaling.” Comprehensive Physiology, vol. 3, no. 3, 2013, pp. 1191-212.

[8] Lefebvre, Philippe, et al. “Role of bile acids and bile acid receptors in metabolic regulation.” Physiological Reviews, vol. 89, no. 4, 2009, pp. 147-191.

[9] Kawamata, Yumiko, et al. “A G Protein-Coupled Receptor Specifically Activated by Bile Acids.” The Journal of Biological Chemistry, vol. 278, no. 11, 2003, pp. 9435-40.

[10] Houten, Sander M., et al. “The role of bile acids in the control of metabolism.” FEBS Letters, vol. 582, no. 16, 2008, pp. 2221-2229.

[11] Sayin, Süleyman I., et al. “Gut Microbiota Regulates Bile Acid Metabolism by Reducing a Primary Bile Acid and Initiating Host FXR Signaling.”Cell Metabolism, vol. 17, no. 4, 2013, pp. 605-15.

[12] Prawitt, Jan, et al. “The Bile Acid Receptor FXR in Cardiovascular and Metabolic Disease.”Nature Reviews Endocrinology, vol. 11, no. 7, 2015, pp. 385-96.

[13] Gadaleta, Remo M., et al. “Farnesoid X Receptor Activation Inhibits Inflammation and Cancer in Two Murine Models of Inflammatory Bowel Disease.”Gastroenterology, vol. 143, no. 5, 2012, pp. 1197-208.

[14] Thomas, Celine, et al. “TGR5-mediated bile acid sensing controls glucose homeostasis.”Cell Metabolism, vol. 10, no. 3, 2009, pp. 167-177.

[15] Fiorucci, Stefano, et al. “Bile acid-activated receptors in the treatment of metabolic disease.”Nature Reviews Gastroenterology & Hepatology, vol. 11, no. 12, 2014, pp. 744-754.